D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights

Exclusion Criteria

• •A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders; organic brain syndrome, cognitive dysfunction that could interfere with capacity to engage in therapy;
• •A history of substance or alcohol dependence (other than nicotine) in the last 6 months or otherwise unable to commit to refraining from alcohol use during the period of study participation.
• •Patients with significant suicidal ideation or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate services.
• •Patients must be off concurrent anxiolytics and beta blockers and on a stable dose of antidepressant medication for at least 3 weeks prior to initiation of randomized treatment.
• •Patients receiving medication that might interfere with study medication (medication that might lower seizure threshold: meperidine or antibiotics in high dosage: penicillins, cephalosporins, amphotericin and imipenem),
• •Patients with a current or past history of seizures
• •Pregnant women, lactating women, and women of childbearing potential who are not using medically accepted effective methods of contraception or abstinence
• •Patients with a history of renal insufficiency (creatinine clearance less than 60 mL/min) or liver insufficiency
• •Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration specifically targeting phobias
• •Patients unable to understand study procedures and participate in the informed consent process.
• •Other serious medical illnesses (e.g., cardiovascular, liver, kidney, respiratory, endocrine, neurologic, or blood-related diseases),
• •Inability to tolerate wearing the Virtual Reality Head Mounted Display,
• •If patients refuse the study medication
• •Any allergic reactions to D-Cycloserine by history